Case Study | December 17, 2007 | Andrew Kenler, M.D.

In-Office Alternative to Surgical Excision of Biopsy-Proven Fibroadenomas Proves Highly Effective

The Visica 2 Treatment System is an effective alternative to surgery for benign breast tumors

Until a year ago, I was treating biopsy-proven fibroadenomas by either observation or surgical excision. While I find surgical excision effective, the drawbacks include the need for general anesthesia, increased patient stress, recovery time, and based on fibroadenoma size — scarring and potential disfigurement. Observation can also be stressful on patients, especially when their fibroademomas are larger than 1 centimeter. Wanting a minimally invasive alternative for my patients with symptomatic fibroadenomas, I identified the Sanarus Visica 2 System that utilizes cryoablation to destroy fibroadenomas. After 12 months of use in my practice, I have found this therapy to be ideal in treating these symptomatic fibroadenomas from both the physician and the patient perspective.
The first advantage of cryoablation over surgery that I noted is that I can treat fibroadenomas quickly and easily in my office. This makes scheduling easier and has helped facilitate more treatments while reducing overall costs to my patients as co-pays are less. When performing Visica treatments, I use ultrasound to guide the cryoprobe into position in the lesion and to monitor a growing ice ball that engulfs the fibroadenoma as it moves through freeze/thaw cycles which destroy the targeted tissue. The Visica 2 treatment also affords me the opportunity to control the iceball size relative to the size of the lesion, giving me the ability to tailor my treatments to specific lesion sizes. The speed of the treatment was surprising. I’ve found treatment times for lesions 2 centimeters to be around 12 minutes. That combined with the use of local anesthesia makes the treatment stress-free on my patients.
Long-term results have also been impressive. Clinical studies have shown no regrowth in over 1,500 cases, which has also been demonstrated in my practice. Resolution has been rapid, especially with tumors under 2 centimeters in size that resolve in less than six months. Additionally, published clinical data demonstrates that cryotherapy does not produce artifacts in follow-up mammograms that would adversely affect interpretation. I have found follow-up mammography to be essentially normal in my patients.
Overall, I would describe the key difference between treating with cryotherapy versus surgical and percutaneous excision as the ability to perform a minimally invasive treatment that destroys the entire fibroadenoma with little or no risk. The ablated tissue essentially “melts away” over time, permanently ridding my patients of the fibroadenoma. They are left with virtually no scarring and no deformity as I’m not removing any tissue from the breast. In fact, the incision needed to accommodate the probe is always around 3 mm whether I treat a 1- or a 4-cm fibroadenoma. The patients have reduced stress because they can have the treatment in my office, and there’s no recovery time so they are immediately back to normal activities.

For more information: www.sanarus.com

Related Content

Improved Imaging Technique Could Increase Chances of Prostate Cancer Survival
News | Prostate Cancer | August 20, 2019
According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their...
News | Biopsy Systems | March 29, 2019
Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy...
FDA Clears Ion Endoluminal Lung Biopsy System
Technology | Interventional Radiology | February 20, 2019
The U.S. Food and Drug Administration (FDA) cleared the Ion endoluminal system from Intuitive Surgical Inc. to enable...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to
Leica Biosystems Launches MammoPort Specimen Containment and Transport System
Technology | Breast Biopsy Systems | October 03, 2018
Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018
Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American urology-specific group...